학술논문
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation
Document Type
article
Author
Li, Jonathan Z; Melberg, Meghan; Kittilson, Autumn; Abdel-Mohsen, Mohamed; Li, Yijia; Aga, Evgenia; Bosch, Ronald J; Wonderlich, Elizabeth R; Kinslow, Jennifer; Giron, Leila B; Di Germanio, Clara; Pilkinton, Mark; MacLaren, Lynsay; Keefer, Michael; Fox, Lawrence; Barr, Liz; Acosta, Edward; Ananworanich, Jintanat; Coombs, Robert; Mellors, John; Deeks, Steven; Gandhi, Rajesh T; Busch, Michael; Landay, Alan; Macatangay, Bernard; Smith, Davey M; Team, for the AIDS Clinical Trials Group A5345 Study
Source
JCI Insight. 9(3)
Subject
Language
Abstract
BACKGROUNDIdentifying factors that predict the timing of HIV rebound after treatment interruption will be crucial for designing and evaluating interventions for HIV remission.METHODSWe performed a broad evaluation of viral and immune factors that predict viral rebound (AIDS Clinical Trials Group A5345). Participants initiated antiretroviral therapy (ART) during chronic (N = 33) or early (N = 12) HIV infection with ≥ 2 years of suppressive ART and restarted ART if they had 2 viral loads ≥ 1,000 copies/mL after treatment interruption.RESULTSCompared with chronic-treated participants, early-treated individuals had smaller and fewer transcriptionally active HIV reservoirs. A higher percentage of HIV Gag-specific CD8+ T cell cytotoxic response was associated with lower intact proviral DNA. Predictors of HIV rebound timing differed between early- versus chronic-treated participants, as the strongest reservoir predictor of time to HIV rebound was level of residual viremia in early-treated participants and intact DNA level in chronic-treated individuals. We also identified distinct sets of pre-treatment interruption viral, immune, and inflammatory markers that differentiated participants who had rapid versus slow rebound.CONCLUSIONThe results provide an in-depth overview of the complex interplay of viral, immunologic, and inflammatory predictors of viral rebound and demonstrate that the timing of ART initiation modifies the features of rapid and slow viral rebound.TRIAL REGISTRATIONClinicalTrials.gov NCT03001128FUNDINGNIH National Institute of Allergy and Infectious Diseases, Merck.